Franklin Resources Inc. Boosts Stake in Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Franklin Resources Inc. lifted its holdings in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTAFree Report) by 34.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,115,817 shares of the company’s stock after buying an additional 283,469 shares during the period. Franklin Resources Inc. owned approximately 1.14% of Centessa Pharmaceuticals worth $8,882,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of CNTA. Trexquant Investment LP bought a new position in shares of Centessa Pharmaceuticals during the 4th quarter valued at $114,000. Jump Financial LLC purchased a new position in Centessa Pharmaceuticals in the fourth quarter worth about $114,000. China Universal Asset Management Co. Ltd. grew its stake in shares of Centessa Pharmaceuticals by 371.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,394 shares of the company’s stock valued at $51,000 after purchasing an additional 5,037 shares during the period. Acuta Capital Partners LLC purchased a new stake in shares of Centessa Pharmaceuticals during the 3rd quarter valued at about $2,092,000. Finally, Adage Capital Partners GP L.L.C. lifted its stake in shares of Centessa Pharmaceuticals by 25.8% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 2,830,500 shares of the company’s stock worth $18,313,000 after purchasing an additional 580,500 shares during the period. 82.01% of the stock is currently owned by institutional investors.

Centessa Pharmaceuticals Price Performance

Shares of CNTA opened at $8.12 on Friday. The company has a 50 day moving average of $9.86 and a two-hundred day moving average of $8.92. The company has a market cap of $815.90 million, a price-to-earnings ratio of -5.72 and a beta of 1.44. The company has a quick ratio of 10.37, a current ratio of 10.37 and a debt-to-equity ratio of 0.36. Centessa Pharmaceuticals plc has a twelve month low of $4.30 and a twelve month high of $12.45.

Centessa Pharmaceuticals (NASDAQ:CNTAGet Free Report) last issued its quarterly earnings results on Thursday, March 28th. The company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.06. The business had revenue of $6.85 million for the quarter. As a group, analysts predict that Centessa Pharmaceuticals plc will post -1.76 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, BMO Capital Markets reiterated an “outperform” rating and set a $15.00 target price on shares of Centessa Pharmaceuticals in a research report on Monday, April 1st. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $10.00.

View Our Latest Stock Report on Centessa Pharmaceuticals

Insider Transactions at Centessa Pharmaceuticals

In related news, insider Karen M. Anderson sold 51,160 shares of the business’s stock in a transaction on Monday, March 25th. The shares were sold at an average price of $11.88, for a total value of $607,780.80. Following the completion of the transaction, the insider now directly owns 71,525 shares in the company, valued at approximately $849,717. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 11.59% of the company’s stock.

Centessa Pharmaceuticals Profile

(Free Report)

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.

Further Reading

Want to see what other hedge funds are holding CNTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Centessa Pharmaceuticals plc (NASDAQ:CNTAFree Report).

Institutional Ownership by Quarter for Centessa Pharmaceuticals (NASDAQ:CNTA)

Receive News & Ratings for Centessa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centessa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.